

Open Peer Review on Qeios

Vatalanib

National Cancer Institute

Source

National Cancer Institute. <u>Vatalanib</u>. NCI Thesaurus. Code C1868.

An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.

Qeios ID: XP87KC · https://doi.org/10.32388/XP87KC